Informatics Framework for Pulmonary Rehabilitation

Status Recruiting

Clinical Trial Summary

Previous studies clearly established clinical benefits of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease however uptake and completion rate of pulmonary rehabilitation programs by these patients is limited by multiple barriers. The goal of this project to systematically evaluate impact of Comprehensive Health Informatics Engagement Framework for Pulmonary Rehabilitation (CHIEF-PR) in a randomized controlled trial. The main hypothesis is that CHIEF-PR will result in significantly higher rates of completion of a comprehensive pulmonary rehabilitation program.

Clinical Trial Description

Previous studies clearly established clinical benefits of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD) however uptake and completion rate of pulmonary rehabilitation (PR) programs by these patients is limited by multiple barriers. The study team developed a Comprehensive Health Informatics Engagement Framework for Pulmonary Rehabilitation which facilitates patient referral and promotes adherence with pulmonary rehabilitation program using innovative multi-pronged approach. It includes computer-mediated patient counseling to increase patient motivation in joining PR program followed by ongoing home-based support of PR by a telerehabilitation system that monitors patients' progress and allows remote oversight by clinical PR team. The goal of this project is to systematically evaluate impact of Comprehensive Health Informatics Engagement Framework for Pulmonary Rehabilitation (CHIEF-PR) in a randomized controlled trial. The study team's main hypothesis is that CHIEF-PR will result in significantly higher rates of completion of a comprehensive pulmonary rehabilitation program. The study team will enroll 120 COPD patients within 4 weeks of acute exacerbation of COPD into a randomized controlled trial and follow them for 12 months. Patients will be randomly assigned to intervention (CHIEF-PR) and control (best available standard of care) groups. Primary outcome will be completion rate of a comprehensive 3-month PR program. Secondary outcomes will include relevant clinical and patient-reported parameters. ;

Study Design

Related Conditions & MeSH terms

COPD

Clinical Trial Details

NCT number	NCT03981783
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact	Joseph Finkelstein, MD
Phone	212-659-9596
Email	Joseph.Finkelstein@mssm.edu
Status	Recruiting
Phase	N/A
Start date	June 11, 2020
Completion date	August 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06000696` - Healthy at Home Pilot
Active, not recruiting	`NCT03927820` - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)	N/A
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Completed	`NCT04105075` - COPD in Obese Patients
Recruiting	`NCT05825261` - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting	`NCT04075331` - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial	Phase 2/Phase 3
Terminated	`NCT03640260` - Respiratory Regulation With Biofeedback in COPD	N/A
Recruiting	`NCT04872309` - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting	`NCT05145894` - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn	`NCT04210050` - Sleep Ventilation for Patients With Advanced Hypercapnic COPD	N/A
Terminated	`NCT03284203` - Feasibility of At-Home Handheld Spirometry	N/A
Recruiting	`NCT06110403` - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness	Phase 1/Phase 2
Active, not recruiting	`NCT06040424` - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients	Phase 3
Recruiting	`NCT05865184` - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting	`NCT04868357` - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program	N/A
Completed	`NCT01892566` - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV	N/A
Completed	`NCT04119856` - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD	N/A
Completed	`NCT04485741` - Strados System at Center of Excellence
Completed	`NCT03626519` - Effects of Menthol on Dyspnoea in COPD Patients	N/A
Recruiting	`NCT04860375` - Multidisciplinary Management of Severe COPD	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Informatics Framework for Pulmonary Rehabilitation — CHIEF-PR

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms